Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, May 12, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Maintained (ATRA) at Hold with Increased Target to $575 on, May 12th, 2020
Anupam Rama of JP Morgan, Maintained "Atara Biotherapeutics, Inc." (ATRA) at Hold with Increased Target from $550 to $575 on, May 12th, 2020.
Anupam has made no other calls on ATRA in the last 4 months.
There is 1 other peer that has a rating on ATRA. Out of the 1 peers that are also analyzing ATRA, 0 agree with Anupam's Rating of Hold.
This is the rating of the analyst that currently disagrees with Anupam
- Yigal Nochomovitz of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, April 23rd, 2020
